For 3Q FY 2012, Alembic Pharmaceuticals is expected to post net sales of Rs.389 cr
and net profit of Rs.31.9 cr. Growth would mainly be driven by exports sales. The
company’s OPM is expected to come in at 14.0% during the period.
Maintain Buy recommendation on the stock with a target price of Rs. 77.
Review by Angel Broking
and net profit of Rs.31.9 cr. Growth would mainly be driven by exports sales. The
company’s OPM is expected to come in at 14.0% during the period.
Maintain Buy recommendation on the stock with a target price of Rs. 77.
Review by Angel Broking
No comments:
Post a Comment